PolyTherics to present recent developments in improving antibody fragments for therapeutic use at PEGS Protein Engineering Summit, Boston
London, United Kingdom – PolyTherics, the biopharmaceuticals company dedicated to precision engineering of protein half-life is pleased to announce its attendance at the 5th Annual PEGS conference in Boston, USA. Dr Ji-won Choi, Head of Biology will present data tomorrow showing that novel recombinant antibody fragments can be selectively modified by PEGylation without compromising their bioactivity. Dr Choi’s presentation will be featured in a session entitled “Recombinant Antibodies: From Concept to Clinic”, at 11.05am, EST.
Based in the London Bioscience Innovation Centre, PolyTherics has an established business in TheraPEG™, the application of polymer-based technology to proteins to develop a broad portfolio of biopharmaceuticals with selectively tailored half-life. PolyTherics’ discoveries have exciting potential for application in the field of next generation therapeutic antibodies.
:“We are delighted to be invited to present our discoveries at PEGS, given its recognition as the essential protein engineering summit for discovery, bioprocess and clinical developments in the field of Recombinant Antibodies and Therapeutic Proteins” comments Dr. Keith Powell, CEO of PolyTherics.
“We plan to use this opportunity to promote our protein PEGylation expertise and seek new collaborative partnerships with antibody product-focused companies”.
The abstract of Dr. Choi’s talk will be available on request following the presentation.
For further information, please contact:
Dr. Keith Powell , CEO +44 (0) 207 691 4928
Mike Wort / Anna Dunphy +44 (0) 207 861 3838
De Facto Communications